|
WO2020168017A1
|
|
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
|
WO2020082057A1
|
|
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
|
CN111212661A
|
|
Interleukin-2 polypeptide conjugates and uses thereof
|
|
CN111417655A
|
|
anti-CD3 antibody folate bioconjugates and uses thereof
|
|
EP3788149A1
|
|
A method for optimizing antibody expression
|
|
KR20200138759A
|
|
Humanized anti-prostate specific membrane antigen (PSMA) antibody drug conjugate
|
|
MX2019014286A
|
|
Methods and compositions for promoting non-natural amino acid-containing protein production.
|
|
US2018319885A1
|
|
Anti-cd3-folate conjugates and their uses
|
|
AU2015203349A1
|
|
Modified insulin polypeptides and their uses
|
|
AU2015202369A1
|
|
Modified leptin polypeptides and their uses
|
|
WO2015143224A1
|
|
Chimeric antigen receptor-modified t-cells
|
|
AU2014274518A1
|
|
Modified relaxin polypeptides and their uses
|
|
TW201446804A
|
|
Novel polypeptide small molecule conjugates and their uses
|
|
AU2014202108A1
|
|
Modified bovine somatotropin polypeptides and their uses
|
|
US2015141624A1
|
|
Anti-CD70 antibody drug conjugates
|
|
CA2876706A1
|
|
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
NZ713941A
|
|
Prostate-specific membrane antigen antibody drug conjugates
|
|
AU2013205030A1
|
|
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
AU2013202836A1
|
|
Modified bovine G-CSF polypeptides and their uses
|
|
AU2013202794A1
|
|
Non-natural amino acid replication-dependent microorganisms and vaccines
|
